#immunocore
Latest news and interesting information about immunocore.
Brenetafusp Shows Promise in Melanoma
Immunocore's brenetafusp showed 14.3-month median overall survival in Phase 1/2 melanoma trial, supporting Phase 3 development.
...
→
EN ▾
Large Construction at Surakhani Market: Traffic DisruptedNetanyahu orders operation in LebanonDrone Strike Damages Zaporizhzhia Nuclear PlantJobs report awaited for soaring US stocksDrivers warned: Visibility to be limited7 clubs earned over €100 million in a seasonColombians Choose Between Left and Right in ElectionTomorrow's weather favorable for weather-sensitive peopleRevolution Medicines Phase 3 Trial ResultsAzerbaijani jiu-jitsu fighter beats Armenian rivalLarge Construction at Surakhani Market: Traffic DisruptedNetanyahu orders operation in LebanonDrone Strike Damages Zaporizhzhia Nuclear PlantJobs report awaited for soaring US stocksDrivers warned: Visibility to be limited7 clubs earned over €100 million in a seasonColombians Choose Between Left and Right in ElectionTomorrow's weather favorable for weather-sensitive peopleRevolution Medicines Phase 3 Trial ResultsAzerbaijani jiu-jitsu fighter beats Armenian rival